Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo Nordisk Says More To Victoza Outcomes Benefit Than A GLP-1 Class Effect

Aug 29 2017

• By Emily Hayes

Diabetes

Related Content

Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too

Dec 05 2016

Sanofi's Lixisenatide Gets Clean Bill Of Health On CV Safety, Heart Failure

Jun 09 2015

CANVAS Trial Results: Better For Janssen, Lilly Or the SGLT2 Class?

Jun 14 2017

Disappointing Bydureon EXSCEL Outcomes Data May Raise Stakes For Victoza

May 23 2017

Advantage Novo As Victoza Gets CV Benefit Okay in Europe

Jul 28 2017

Novo Readies For Victoza CV Benefit Claim With US FDA Panel Nod

Jun 21 2017

Novo’s Victoza CV Benefit Claim Could Be Narrowed With FDA Panel Vote

Jun 21 2017

Related Companies

Novo Nordisk A/S

Boehringer Ingelheim GmbH

Eli Lilly and Company

Johnson & Johnson

Sanofi

AstraZeneca PLC

Additional Topics

Approvals Research & Development Regulation Metabolic Disorders BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window